BCR and B-cell chronic lymphocytic leukemia: While the use of BCR-targeted oral agents ibrutinib (BTK-inhibitor) and idelalisib (PI3Kδ-inhibitor) has been shown to be effective in relapsed/refractory CLL patients, the responses are limited to partial remissions [4].